High-dose therapy with iodine-131-labeled monoclonal antibody CC49 in patients with gastrointestinal cancers: a phase I trial

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M TemperoD Colcher

Abstract

A phase I trial that evaluated for extrahematopoietic toxicity was conducted with iodine-131 (131I) labeled monoclonal antibody (MAb) CC49. Correlative studies included pharmacokinetic and biodistribution analyses, estimates of absorbed radiation dose, and measurement of human antimonoclonal antibodies (HAMA). After collection and cryopreservation of hematopoietic stem cells, 15 patients with gastrointestinal cancers were administered a tracer dose of 131I-MAb CC49. Within 5 to 6 days, 14 patients (two to three per activity level) underwent a single treatment with 131I-MAb CC49 (50, 100, 150, 200, 250, and 300 mCi/m2). Biodistribution was determined using planar and single photon emission computer tomographic (SPECT) imaging. Pharmacokinetic studies were performed by measuring radioactivity in serial blood samples. In some patients, biopsies of metastases and related normal tissues were obtained for radioactivity measurements. Radiation dosimetry estimates were calculated using available biodistribution, pharmacokinetic, and tissue biopsy data. Toxicity was evaluated using the National Cancer Institute (NCI) Common Toxicity Criteria. No dose-limiting extrahematopoietic toxicity was identified. Twelve patients experienced grade ...Continue Reading

Citations

Jun 12, 2002·Bone Marrow Transplantation·J M PagelO W Press
Oct 27, 2005·Cancer Biotherapy & Radiopharmaceuticals·Buck E RogersDonald J Buchsbaum
Feb 8, 2008·Cancer Immunology, Immunotherapy : CII·Mala ChakrabortyJames W Hodge
Apr 18, 2003·Cancer Immunology, Immunotherapy : CII·David M Goldenberg
Apr 2, 2002·World Journal of Gastroenterology : WJG·Feng-Tian HeYan Zhang
Oct 17, 2018·Expert Opinion on Pharmacotherapy·Jennifer L Olson, Richard J Bold
Dec 18, 2001·International Journal of Cancer. Journal International Du Cancer·G PavlinkovaS K Batra
Sep 5, 2003·Cancer Biotherapy & Radiopharmaceuticals·Ruby MeredithAlbert LoBuglio
Nov 9, 2011·Nature Reviews. Clinical Oncology·Jean-Pierre PougetDavid Azria
May 4, 2013·Immunotherapy·Isabelle Navarro-TeulonJean-Pierre Pouget
Mar 28, 2018·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Amber Draper
Mar 28, 2002·Cancer Biotherapy & Radiopharmaceuticals·Hazel Breitz
Mar 15, 2011·Immunotherapy·Robert M Sharkey, David M Goldenberg
Jan 11, 2013·Cancer Control : Journal of the Moffitt Cancer Center·Michael B TomblynPaul E Wallner
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rhona SteinDavid M Goldenberg
May 7, 2003·Peptides·Gabriela PavlinkovaJanina Baranowska-Kortylewicz
Mar 23, 2000·Seminars in Radiation Oncology·D E Milenic

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.